CCND2 rearrangements are the most frequent genetic events in cyclin D1− mantle cell lymphoma

  • Itziar Salaverria
    Department of Pathology, Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;
  • Cristina Royo
    Department of Pathology, Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;
  • Alejandra Carvajal-Cuenca
    Department of Pathology, Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;
  • Guillem Clot
    Department of Pathology, Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;
  • Alba Navarro
    Department of Pathology, Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;
  • Alejandra Valera
    Department of Pathology, Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;
  • Joo Y. Song
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;
  • Renata Woroniecka
    Cytogenetic Laboratory, and
  • Grzegorz Rymkiewicz
    Department of Pathology, The Maria Skłodowska-Curie Memorial Institute and Oncology Centre, Warsaw, Poland;
  • Wolfram Klapper
    Department of Pathology, Hematopathology Section and Lymph Node Registry, Christian Albrechts University, Kiel, Germany;
  • Elena M. Hartmann
    Institute of Pathology, University of Würzburg, Würzburg, Germany;
  • Pierre Sujobert
    Henri Mondor Hospital, Creteil, France;
  • Iwona Wlodarska
    Center for Human Genetics, KU Leuven, Leuven, Belgium;
  • Judith A. Ferry
    Department of Pathology, Massachusetts General Hospital, Boston, MA;
  • Philippe Gaulard
    Henri Mondor Hospital, Creteil, France;
  • German Ott
    Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany;
  • Andreas Rosenwald
    Institute of Pathology, University of Würzburg, Würzburg, Germany;
  • Armando Lopez-Guillermo
    Department of Hematology, Hematopathology Unit, Hospital Clínic, Barcelona, Spain; and
  • Leticia Quintanilla-Martinez
    Institute of Pathology, Eberhard-Karls-University of Tübingen, Tübingen, Germany
  • Nancy L. Harris
    Department of Pathology, Massachusetts General Hospital, Boston, MA;
  • Elaine S. Jaffe
    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;
  • Reiner Siebert
    Institute of Human Genetics, University Hospital Schleswig-Holstein Campus Kiel/Christian-Albrechts University, Kiel, Germany;
  • Elias Campo
    Department of Pathology, Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;
  • Sílvia Beà
    Department of Pathology, Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;

Description

<jats:title>Key Points</jats:title> <jats:p>This report describes a multidisciplinary study characterizing the largest series of cyclin D1− MCL patients. CCND2 translocations are the most frequent genetic event (55%) in cyclin D1− MCL.</jats:p>

Journal

  • Blood

    Blood 121 (8), 1394-1402, 2013-02-21

    American Society of Hematology

Citations (4)*help

See more

Details 詳細情報について

Report a problem

Back to top